Scientific advisers of Genesys Pharma Inc. (VSE:GPI) willreview the progress of the company's AIDS antisensecompound DNS-BP2R at an April 19 meeting to determine thenature of filings for submitting an investigative new drugapplication and patent application, the Vancouver, BritishColumbia, company announced.
Testing at the Manitoba Institute of Cell Biology has shown thedrug does block production of proteins essential for replicationof the AIDS virus. The drug is now being tested with live virusat Lady Davis Research Institute at McGill University inMontreal.
(c) 1997 American Health Consultants. All rights reserved.